[go: up one dir, main page]

ZA200810577B - Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3) - Google Patents

Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3)

Info

Publication number
ZA200810577B
ZA200810577B ZA200810577A ZA200810577A ZA200810577B ZA 200810577 B ZA200810577 B ZA 200810577B ZA 200810577 A ZA200810577 A ZA 200810577A ZA 200810577 A ZA200810577 A ZA 200810577A ZA 200810577 B ZA200810577 B ZA 200810577B
Authority
ZA
South Africa
Prior art keywords
gsk3
imidazol
treatment
diseases related
pyrimidine derivatives
Prior art date
Application number
ZA200810577A
Other languages
English (en)
Inventor
Burrows Jeremy
Huerta Fernando
Rein Tobias
Rotticci Didier
Staaf Karin
Turek Dominika
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200810577(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200810577B publication Critical patent/ZA200810577B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200810577A 2006-06-27 2008-12-12 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3) ZA200810577B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81675506P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
ZA200810577B true ZA200810577B (en) 2009-08-26

Family

ID=38846128

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810577A ZA200810577B (en) 2006-06-27 2008-12-12 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3)

Country Status (19)

Country Link
US (1) US20080188503A1 (fr)
EP (1) EP2046783A4 (fr)
JP (1) JP2009542639A (fr)
KR (1) KR20090024295A (fr)
CN (1) CN101511824A (fr)
AR (1) AR061653A1 (fr)
AU (1) AU2007265732A1 (fr)
BR (1) BRPI0713578A2 (fr)
CA (1) CA2655444A1 (fr)
CL (1) CL2007001882A1 (fr)
EC (1) ECSP088974A (fr)
IL (1) IL195665A0 (fr)
MX (1) MX2008015721A (fr)
NO (1) NO20090328L (fr)
RU (1) RU2008148903A (fr)
TW (1) TW200815417A (fr)
UY (1) UY30438A1 (fr)
WO (1) WO2008002245A2 (fr)
ZA (1) ZA200810577B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
RU2011140238A (ru) * 2009-04-15 2013-05-20 Астразенека Аб Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012050517A1 (fr) * 2010-10-14 2012-04-19 Astrazeneca Ab Pyrimidine substituée par imidazole ayant une puissance élevée d'inhibition de la gsk3 ainsi qu'une sélectivité pan-kinases
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2016008966A1 (fr) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le traitement de maladies liées à la jonction neuromusculaire
WO2016207366A1 (fr) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement d'infections virales
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
KR102206111B1 (ko) 2019-04-01 2021-01-22 박광호 목욕탕용 담수 및 해수 가열시스템
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
EP4289835A4 (fr) * 2021-02-05 2024-08-28 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Inhibiteur de cdk
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (fr) 2021-12-10 2023-06-15 Incyte Corporation Amines bicycliques utilisées comme inhibiteurs de cdk12

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
AU2005315392B2 (en) * 2004-12-17 2010-03-11 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I

Also Published As

Publication number Publication date
CA2655444A1 (fr) 2008-01-03
AU2007265732A1 (en) 2008-01-03
WO2008002245A3 (fr) 2008-02-14
EP2046783A2 (fr) 2009-04-15
NO20090328L (no) 2009-01-26
WO2008002245A8 (fr) 2008-10-09
IL195665A0 (en) 2009-09-01
JP2009542639A (ja) 2009-12-03
MX2008015721A (es) 2009-01-08
KR20090024295A (ko) 2009-03-06
WO2008002245A2 (fr) 2008-01-03
AR061653A1 (es) 2008-09-10
UY30438A1 (es) 2008-01-31
BRPI0713578A2 (pt) 2012-10-23
RU2008148903A (ru) 2010-08-10
CN101511824A (zh) 2009-08-19
CL2007001882A1 (es) 2008-02-08
US20080188503A1 (en) 2008-08-07
EP2046783A4 (fr) 2010-08-04
ECSP088974A (es) 2009-01-30
TW200815417A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
IL195665A0 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
IL195666A0 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EP2237664A4 (fr) Dérivés de (hét)aryl-p-quinone pour le traitement de maladies mitochondriales
PL2120932T3 (pl) Indazolowe pochodne jako inhibitory kinazy do leczenia raka
PT2349260E (pt) Inibidores janus quinase para o tratamento do olho seco e outras doenças relacionadas com o olho
ZA200810673B (en) 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
SI2125822T1 (sl) Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
IL195864A0 (en) 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
ZA200806150B (en) Therapeutic uses of inhibitors of RTP801
PT2097457T (pt) Derivados de polissacarídeos ácidos
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
ZA200904912B (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PT1847524E (pt) Derivados de terfenilo para o tratamento da doença de alzheimer
IL196469A0 (en) New medical use of triazine derivatives
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
ZA201008026B (en) Inhibitors of ikk-b serine-threonine protein kinase
GB0624963D0 (en) Derivatives of 188-Glycyrrhetinic Acid
IL212170A0 (en) Atropisomers of (hydroxyalkyl) pyrrole derivatives
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
HK1130785A (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
HK1130784A (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EP2250178A4 (fr) Procédé amélioré destiné à la préparation de dérivés de triazol-benzodiazépine